How often is BPC-157 dosed?

No established human dosing protocol

BPC-157 is not FDA-approved and has no completed human dosing trial. The frequencies and amounts repeated across the research community — including named influencer protocols — are convention, not figures derived from a controlled study. This page reports that state honestly rather than presenting convention as an answer.

What the cited literature actually studied

Most of the cited BPC-157 literature is animal-model work examining mechanism and tissue repair, not a dosing schedule. The one cited human report is a small case series in which patients with chronic knee pain received a single localized injection, with no standardized dose or frequency established; a registered Phase-1 oral trial has no published results.

For how BPC-157 and TB-500 compare as research peptides, see the BPC-157 vs TB-500 comparison.

• No human clinical trial has established a dosing frequency.
• The circulating once/twice-daily figures are community convention, not trial data.
• The one cited human datum is a single localized injection (no dose reported).
• Most cited evidence is animal-model, on mechanism and healing.